Mesalamine + Canasa + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Proctitis
Conditions
Proctitis
Trial Timeline
Jun 1, 2010 → Dec 1, 2012
NCT ID
NCT01172444About Mesalamine + Canasa + Placebo
Mesalamine + Canasa + Placebo is a phase 3 stage product being developed by Sandoz Group for Proctitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01172444. Target conditions include Proctitis.
What happened to similar drugs?
0 of 3 similar drugs in Proctitis were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01172444 | Phase 3 | Terminated |
Competing Products
3 competing products in Proctitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Budesonide + Placebo | Bausch Health | Phase 3 | 34 |
| Budesonide Foam | Bausch Health | Phase 3 | 26 |
| Budesonide + Placebo | Bausch Health | Phase 3 | 34 |